Concentration of Business Revenue and Accounts Receivable in Stemline
First written in FY2019. 16 of 20 entries say "Restated". Latest entry: FY2025.
CanBas moved to the "Worse" side of this theme in 2025, 2 years after the typical company in this theme (2023).
The whole theme swung hardest in 2017: 12 of 76 companies on the "Worse" side.
28 other companies' latest entry also says "Worsened".
- FY2025WorsenedAnnual report
「As of the end of the current fiscal year, approximately 99% of other receivables were one-off foreign-currency-denominated receivables from a specific company.」
The concentration ratio of one-off foreign-currency-denominated other receivables from a specific company increased from approximately 94% in the previous fiscal year to approximately 99%. - FY2025-H1RestatedAnnual report
「Revenue from this partnership is not currently being generated.」
Revenue from the partnership with Stemline, which had supported business revenue in the past, continued not to be generated during the current interim accounting period. - FY2024Explicit disclosure of concentration of other receivables with a specific companyAnnual report
「As of the end of the current fiscal year, approximately 94% of other receivables were one-off foreign-currency-denominated receivables from a specific company.」
While no partnership revenue from Stemline was generated, the company newly specified that approximately 94% of other receivables were one-off foreign-currency-denominated receivables from a specific company. - FY2024-Q3RestatedAnnual report
「Revenue from this partnership is not currently being generated.」
Revenue from the partnership with Stemline, which had supported business revenue in the past, continued not to be generated during the cumulative third-quarter period. - FY2024-Q1RestatedAnnual report
「Revenue from this partnership is not currently being generated.」
Revenue from the partnership with Stemline, which had supported business revenue in the past, continued not to be generated during the first quarter. - FY2023-Q3RestatedAnnual report
「The company has entered into a license agreement with Stemline granting exclusive worldwide rights to develop, manufacture and commercialize the compound. No revenue from this alliance is currently being generated.」
Revenue from the partnership with Stemline, which had supported business revenue in the past, continued not to be generated during the cumulative third-quarter period. - FY2023-Q2RestatedAnnual report
「The company has entered into a license agreement with Stemline granting exclusive worldwide rights to develop, manufacture and commercialize the compound. No revenue from this alliance is currently being generated.」
Revenue from the partnership with Stemline, which had supported business revenue in the past, continued not to be generated during the cumulative second-quarter period. - FY2022RestatedAnnual report
「There were no sales during the current fiscal year.」
Technical advisory fee revenue from Stemline, which had previously supported business revenue, was also not generated during the current fiscal year, reconfirming the absence of sales to external customers. - FY2022-Q3RestatedAnnual report
「The company has entered into a license agreement with Stemline granting exclusive worldwide rights to develop, manufacture and commercialize the compound. No revenue from this alliance is currently being generated.」
The company reconfirms that revenue from the partnership with Stemline, which had supported business revenue in the past, was not generated in the current quarter either. - FY2022-Q2RestatedAnnual report
「The company has entered into a license agreement with Stemline granting exclusive worldwide rights to develop, manufacture and commercialize the compound. No revenue from this alliance is currently being generated.」
The company reconfirms that technical advisory fees and other revenue from Stemline, which had previously accounted for most business revenue, were not generated in the current quarter either. - FY2022-Q1No revenue from the Stemline partnershipAnnual report
「Revenue from this partnership is not currently being generated.」
Technical advisory fees from Stemline had previously accounted for all business revenue, but the company stated that no revenue from the partnership was being generated in the current quarter. - FY2021RestatedAnnual report
「Stemline Therapeutics, Inc. 108,945 100.0」
All ¥108.945 million of business revenue for the current fiscal year was from Stemline, and revenue remained concentrated with a specific partner. - FY2021-Q3RestatedAnnual report
「Accordingly, we recognized a technical advisory fee of ¥82.812 million as business revenue for the cumulative third-quarter period.」
Technical advisory fees from Stemline again constituted business revenue for the cumulative third-quarter period, and revenue remained concentrated with a specific partner. - FY2021-Q2RestatedAnnual report
「Accordingly, we recognized a technical advisory fee of ¥55.464 million as business revenue for the cumulative second-quarter period.」
Technical advisory fees from Stemline again constituted business revenue for the cumulative second-quarter period, and revenue remained concentrated with a specific partner. - FY2021-Q1RestatedAnnual report
「Accordingly, we recognized a technical advisory fee of ¥27.726 million as business revenue for the cumulative first-quarter period.」
Technical advisory fees from Stemline again constituted business revenue in the first quarter, and revenue remained concentrated with a specific partner. - FY2020RestatedAnnual report
「Stemline Therapeutics, Inc. 110,000 100.0」
All ¥110 million of business revenue for the current fiscal year was from Stemline, and revenue remained concentrated with a specific partner. Accounts receivable of ¥56.054 million were also from Stemline. - FY2020-Q3RestatedAnnual report
「Accordingly, we recognized a technical advisory fee of ¥82.575 million as business revenue for the cumulative third-quarter period.」
The company also recognized a technical advisory fee from Stemline as business revenue this quarter, indicating that revenue remains concentrated with a specific partner. - FY2020-Q2RestatedAnnual report
「Accordingly, we recognized a technical advisory fee of ¥55.452 million as business revenue for the cumulative second-quarter period.」
The company also recognized a technical advisory fee from Stemline as business revenue this quarter, indicating that revenue remains concentrated with a specific partner. - FY2020-Q1RestatedAnnual report
「Accordingly, we recognized a technical advisory fee of ¥27.726 million as business revenue for the cumulative first-quarter period.」
The company also recognized a technical advisory fee from Stemline as business revenue this quarter, indicating that revenue remains concentrated with a specific partner. - FY2019First statedAnnual report
「As of the balance-sheet date for the current fiscal year, all accounts receivable were from a specific customer.」
Stemline Therapeutics, Inc. accounted for 100.0% of the ¥115.55 million in business revenue for the current fiscal year, and all accounts receivable as of the balance-sheet date were also from a specific customer. This newly discloses the concentration of revenue and receivables with a customer as a risk.